For kinase-type PCCs, whether RET inhibitors can enhance the antigen presentation ability of tumor cells, and further provide chance for combination of kinase-targeted therapy and immunotherapy, needs to be verified by follow-up research. The gene discussed is RET; the disease is neoplasm.